KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Rating of “Moderate Buy” from Analysts

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has received a consensus rating of “Moderate Buy” from the eight analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $32.60.

A number of analysts have weighed in on KALV shares. TD Cowen reissued a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. HC Wainwright upped their target price on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a report on Friday, January 9th. Stifel Nicolaus increased their target price on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Citizens Jmp cut their price target on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a research note on Thursday, March 26th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ KALV opened at $20.13 on Wednesday. The stock’s 50-day simple moving average is $16.22 and its 200-day simple moving average is $14.52. The firm has a market capitalization of $1.03 billion, a PE ratio of -5.10 and a beta of -0.35. KalVista Pharmaceuticals has a fifty-two week low of $9.23 and a fifty-two week high of $20.59. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22.

Insider Buying and Selling at KalVista Pharmaceuticals

In related news, CFO Brian Piekos sold 1,767 shares of the company’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $27,512.19. Following the completion of the sale, the chief financial officer directly owned 13,762 shares of the company’s stock, valued at $214,274.34. This represents a 11.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Nicole Sweeny sold 3,975 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $61,890.75. Following the transaction, the insider owned 47,003 shares in the company, valued at $731,836.71. This represents a 7.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 248,009 shares of company stock valued at $4,213,467. 4.30% of the stock is owned by insiders.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several large investors have recently modified their holdings of the company. BNP Paribas Financial Markets increased its holdings in shares of KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after acquiring an additional 1,292 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in KalVista Pharmaceuticals during the 3rd quarter worth $55,000. Wolverine Asset Management LLC acquired a new stake in KalVista Pharmaceuticals during the 3rd quarter worth $57,000. KLP Kapitalforvaltning AS purchased a new position in KalVista Pharmaceuticals during the 3rd quarter worth $63,000. Finally, Truvestments Capital LLC grew its position in KalVista Pharmaceuticals by 253.8% during the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock worth $76,000 after purchasing an additional 3,360 shares during the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.